NCT00667342 · OUTCOME

Ktrans by Good and Poor Response

A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma · Source last updated 2023-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: min(-1)
Interval / dispersion: Standard Error
Time frame: at week 10 after start of therapy

What was measured

The response is based on the Huvos grade of histologic response for DCE-MRI comparisons and is defined as good for ≥90% necrosis and poor for less than 90%.

Analysis population: Two Stratum A participants with no histologic response were excluded.

Groups in this outcome

All Participants

All 42 evaluable participants in this study had osteosarcoma. This analysis includes 29 Stratum A participants who had primary tumors potentially resectable by aggressive surgery, such as limb-salvage surgery or amputation, and no evidence of metastasis, and 11 Stratum C participants who had metastatic tumors.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
All Participants	40

Reported measurements

Poor Response

Values in min(-1) · Interval/dispersion: Standard Error
Group	Value	Spread	Lower	Upper	Comment
All Participants	0.0775	0.0089	Not reported	Not reported	Not reported

Good Response

Values in min(-1) · Interval/dispersion: Standard Error
Group	Value	Spread	Lower	Upper	Comment
All Participants	0.0491	0.0053	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
0.0089
value
0.0775
title
Poor Response
categories
measurements
group Id
OG000
spread
0.0053
value
0.0491
title
Good Response

denoms

counts
group Id
OG000
value
40
units
Participants

description

The response is based on the Huvos grade of histologic response for DCE-MRI comparisons and is defined as good for ≥90% necrosis and poor for less than 90%.

dispersion Type

Standard Error

groups

description
All 42 evaluable participants in this study had osteosarcoma. This analysis includes 29 Stratum A participants who had primary tumors potentially resectable by aggressive surgery, such as limb-salvage surgery or amputation, and no evidence of metastasis, and 11 Stratum C participants who had metastatic tumors.
id
OG000
title
All Participants

param Type

MEAN

population Description

Two Stratum A participants with no histologic response were excluded.

reporting Status

POSTED

time Frame

at week 10 after start of therapy

title

Ktrans by Good and Poor Response

type

SECONDARY

unit Of Measure

min(-1)

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice